Discussing a first of its kind drug, amivantamab, a bispecific (MET & EGFR) monoclonal antibody just approved for advanced exon20 insertion NSCLC (2nd line).
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
